WALTHAM, Mass., Sept. 28, 2017 /PRNewswire/ -- Alere Inc.
(NYSE: ALR) (the "Company"), a global leader in rapid diagnostic
tests, today announced that it has reached a settlement with the
United States Securities and Exchange Commission (the "SEC") in
connection with the SEC's previously disclosed investigation. The
SEC investigation primarily involved certain accounting and other
matters occurring at foreign subsidiaries previously acquired by
the Company.
Alere issued the following statement:
We have cooperated with the SEC
and we are pleased to fully resolve this matter.
Under the terms of the settlement, Alere agreed to pay
approximately $13 million to the SEC
and consented to the entry by the SEC of an administrative
cease-and-desist order, issued today by the SEC, without admitting
or denying the findings in the order.
About Alere
Alere believes that when diagnosing
and monitoring health conditions, Knowing now matters™. Alere
delivers reliable and actionable information by providing rapid
diagnostic tests, enhancing clinical and economic healthcare
outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid
diagnostics for cardiometabolic disease, infectious disease and
toxicology.
For more information on Alere, please visit www.alere.com.
View original
content:http://www.prnewswire.com/news-releases/alere-announces-settlement-with-sec-300527648.html
SOURCE Alere Inc.